Bioequivalence study of BHV-0223 in patients with amyotrophic lateral sclerosis
Phase of Trial: Phase I
Latest Information Update: 02 Oct 2017
At a glance
- Drugs Riluzole (Primary) ; Riluzole
- Indications Amyotrophic lateral sclerosis
- Focus Pharmacokinetics
- 02 Oct 2017 According to a Biohaven Pharmaceutical media release, this study is expected to begin in the fourth quarter of 2017.
- 12 Jul 2017 Based on the results of this trial, the company expects to submit an NDA for BHV-0223 for ALS in 2018 according to a Portage Biotech media release.
- 16 Jun 2017 According to a Biohaven Pharmaceutical media release, this study is planned to launch in the second half of 2017.